Click here if you are having trouble viewing this message.

2015 TIDO Annual Report released

Fiscal Year 2015 was a year of growth at TIDO. Boston Children’s executed 48 licenses in FY15, a 42 percent increase over the prior year, while the total number of executed industry research and license agreements reached 91, an increase of 17 percent over the prior year. The report highlights selected agreements, Technology Development Fund award winners, and some of our technologies available for licensing. 

Join us at BIO 2016

RSVP today for the Propel Pediatrics partnering reception at VOLTA Restaurant on Tuesday, June 7th, 6-9 pm, in conjunction with the 2016 BIO International Convention in San Francisco. The reception features live programming, great food and specialty cocktails, and a raffle for a Apple products.

This partnering reception brings together leading pharmaceutical and biotech companies, research institutions and patient advocates to establish and expand meaningful collaborations to advance life-saving solutions that address significant challenges facing pediatric healthcare.

Highlighted Technologies

Novel age-specific vaccine testing platform
Keywords: Vaccine, Research tool, Immunology, Platform
Lead InvestigatorsOfer Levy, MD, PhD

Novel use of senicapoc to treat or prevent malaria
Keywords: Therapeutic, Infectious diseases, Malaria
Lead Investigators: Venee Tubman, MD, MMSc

Improving DNA repair efficiency for CRISPR/Cas9-mediated genome editing
Keywords: Therapeutics, Drug development, Research tool, Gene therapy, Gene editing
Lead Investigator: Derrick Rossi, PhD


Microbiome therapeutics: 6 takeaways from a MassBio panel

Seeing the surprising success of “poop pills” in gastrointestinal C. difficile infection, pharma companies and startups are embracing the microbiome as a new therapeutic target for an astonishing range of maladies. To learn what pioneering companies in the space are thinking about the hope and the hype, we recently attended a panel on microbiome therapeutics at the MassBio Annual Meeting and reported the key takeaways that everyone should know.

Boston Children's Startup News

Orchard Therapeutics was launched. The company was co-founded by David Williams, MD, President of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Chief, Hematology/Oncology, Alessandra Biffi, MD, Director, Gene Therapy Program, and Luigi Notarangelo, MD, Director, Research and Molecular Diagnosis Program on Primary Immunodeficiencies, along with University College London, Great Ormond Street Hospital for Children NHS Foundation Trust, the University of Manchester, and the University of California Los Angeles. The company launched with a £21 M Series A financing led by F-Prime Capital. Orchard’s development programs use ex vivo autologous hematopoietic stem cell gene therapy to restore normal gene function in primary immune deficiencies, metabolic diseases and hematological disorders. 

Emulate, Inc.,  a company founded by Donald Ingber, MD, PhD, Vascular Biology Program, around research conducted at BCH and the Wyss Institute, announced that it has secured a $28 M Series B financing. Emulate is focused on the commercialization of their Organs-on-Chips technology, which mimics human biology and disease states by recreating organ microenvironments.